Navigation Links
Professor K. C. Nicolaou Speaks at WuXi AppTec

SHANGHAI, March 17 /PRNewswire-Asia/ -- WuXi AppTec is honored to have Prof. K. C. Nicolaou, the leading authority of the world on natural product total synthesis, as a WuXi AppTec Science Seminar Series lecturer to share his experience and expertise with our company's scientists today. Total Synthesis is a process of creating complex organic molecules from simpler compounds.

(Logo: )

The WuXi AppTec Science Seminar Series is a monthly program that invites the world's top scientific minds and leaders in the pharmaceutical industry to speak with our company's scientists. The program aims to keep them informed about the latest developments in a broad range of topics in pharmaceutical research and development.

Dr. Nicolaou received his Ph.D. from University College London in 1972. From 1972 to 1976, he conducted postdoctoral research, first under Professor T.J. Katz of Columbia University and later under Professor E.J. Corey of Harvard University. He then joined the faculty at the University of Pennsylvania, where he became the Rhodes-Thompson Professor of Chemistry. In 1989, he accepted joint appointments at the University of California, San Diego, where he is Professor of Chemistry, and at the Scripps Research Institute, where he is the Chairman of the Department of Chemistry and holds the Skaggs Professorship of Chemical Biology and the Darlene Shiley Chair in Chemistry.

Dr. Nicolaou is a member of the New York Academy of Sciences, a fellow of the American Academy of Arts and Sciences, a member of the National Academy of Sciences, a fellow of the American Association for the Advancement of Science, and a foreign member of the Academy of Athens. He holds numerous honorary degrees from leading universities. He is author or co-author of more than 60 patents, more than 675 publications, and four books, including textbooks on total synthesis.

"I'm especially pleased to have Dr. Nicolaou here in Shanghai to share his knowledge of organic synthesis," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec. "WuXi AppTec is one of the largest employers of synthetic chemists in the world. We will apply the messages in his lecture to our efforts to produce bioactive molecules for the world's leading pharmaceutical companies."

About WuXi AppTec and WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: .

    For more information, please contact:

     Sherry Shao
     WuXi PharmaTech (Cayman) Inc.
     Tel:   +86-21-5046-4002

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Nyenrode Honorary Doctorate for Professor Michael E. Porter
2. Thin films research lands engineering professor Air Force Young Investigator Award
3. Gift Aids Professor's Research into Vein Treatment
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. UCF professor develops vaccine to protect against black plague bioterror attack
6. Yale professor T.P. Ma awarded the Connecticut Medal of Technology
7. Stuart Parkin first distinguished professor at Eindhoven University of Technology
8. UCF professor develops vaccine to protect against black plague bioterror attack
9. Professor-turned-producer learns the movie biz
10. Professors Marc Feldmann and Sir Ravinder Maini Named Winners of the 2008 Dr. Paul Janssen Award for Biomedical Research
11. Professor Toh-Ming Lu named fellow of the Materials Research Society
Post Your Comments:
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... announced the launch of the Supplyframe Design Lab . Located in Pasadena, ... explore the future of how hardware projects are designed, built and brought to ...
(Date:6/23/2016)...  Blueprint Bio, a company dedicated to identifying, protecting ... has closed its Series A funding round, according to ... "We have received a commitment from Forentis Fund that ... meet our current goals," stated Matthew Nunez . ... complete validation on the current projects in our pipeline, ...
Breaking Biology Technology:
(Date:5/12/2016)... 2016 , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):